Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride

Journal of Cerebral Blood Flow and Metabolism

Volumn 31, Issue 1, 2011, Pages 293-304

  Slifstein, Mark ^a,b   Suckow, Raymond F ^b   Javitch, Jonathan A ^a,b   Cooper, Thomas ^b   Lieberman, Jeffrey ^a,b   Abi Dargham, Anissa ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

11C NNC112; D1 agonist; DAR 0100A; dopamine D1 receptors; PET; positron emission tomography

Indexed keywords

5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; CARBON 11; DAR 0100A; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR; RACLOPRIDE; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BLOOD PRESSURE MEASUREMENT; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RECEPTOR BINDING; ENANTIOMER; IN VIVO STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY;

ANIMALS; BENZAZEPINES; BLOOD PRESSURE; CEREBRAL CORTEX; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; PAPIO ANUBIS; PHENANTHRIDINES; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 78650883892     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/jcbfm.2010.91     Document Type: Article

References (38)

1. Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, Anjilvel S, Pidcock J, Guo NN, Lombardo I, Mann JJ, Van Heertum R, Foged C, Halldin C, Laruelle M (2000a) Measurement of striatal and extrastriatal dopamine D-1 receptor binding potential with [C-11]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab 20:225-43
2. Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, Pidcock J, Guo N, Lombardo I, van Heertum R, Foged C, Halldin C, Mann JJ, Laruelle M (2000b) Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab 20:225-43
3. Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea-Ponce Y, Lombardo I, Van Heertum R, Mann JJ, Foged C, Halldin C, Laruelle M (1999) PET studies of binding competition between endogenous dopamine and the D-1 radiotracer [C-11]NNC 756. Synapse 32:93-109
4. Aleman A, Hijman R, de Haan EHF, Kahn RS (1999) Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 156:1358-66
5. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS (1994) Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology 116:143-51
6. Burnham K, Anderson D (1998) Model Selection and Inference: A Practical Information Theoretic Approach. New York: Springer, 353pp
7. Castner SA, Williams GV, Goldman-Rakic PS (2000) Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287:2020-2
8. Dumartin B, Caille I, Gonon F, Bloch B (1998) Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J Neurosci 18:1650-61
9. Durstewitz D, Seamans JK (2002) The computational role of dopamine D1 receptors in working memory. Neural Netw 15:561-72
10. Durstewitz D, Seamans JK (2008) The dual-state theory of prefrontal cortex dopamine function with relevance to Catechol-O-Methyltransferase genotypes and schizophrenia. Biol Psychiatry 64:739-49
11. Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo NN, Hwang Y, Hwang DR, Abi-Dargham A, Laruelle M (2007) In vivo DA D-1 receptor selectivity of NNC 112 and SCH 23390. Mol Imaging Biol 9:117-25
12. Endres CJ, Carson RE (1998) Assessment of dynamic neurotransmitter changes with bolus or infusion delivery of neuroreceptor ligands. J Cereb Blood Flow Metab 18:1196-210
13. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C (2008) Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74:59-69
14. Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frakowiak RSJ (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189-210
15. George MS, Molnar CE, Grenesko EL, Anderson B, Mu QW, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang XM, Nichols DE, Mailman RB (2007) A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D-1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res 93:42-50 (Pubitemid 46817947)
16. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV (2004) Targeting the dopamine D-1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 174:3-16
17. Guo N, Guo W, Jiang M, Schieren I, Narendran R, Slifstein M, Abi-Dargham A, Javitch J, Laruelle M, Rayport S (2010) Impact of D2 receptor internalization on binding affinity of positron emission tomography radiotracers. Neuropsychopharmacology 35:806-17
18. Innis RB, Cunningham VJ, Delforge J, Fujita M, Giedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Lida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-9
19. Kara E, Lin H, Strange P (2010) Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics. J Neurochem 112: 1442-53
20. Kegeles LS, Slifstein M, Frankle WG, Xu XY, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A (2008) Dose-occupancy study of striatal and extrastriatal dopamine D-2 receptors by aripiprazole in schizophrenia with PET and [F-18] Fallypride. Neuropsychopharmacology 33: 3111-3125
21. Kenakin TP (1986) Receptor reserve as a tissue misnomer. Trends Pharmacol Sci 7:93-5
22. Knoerzer TA, Nichols DE, Brewster WK, Watts VJ, Mottola D, Mailman RB (1994) Dopaminergic benzo[a]-phenanthridines-resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D-1 dopamine-receptor agonist. J Med Chem 37:2453-60
23. Kong MMC, Fan T, Varghese G, O'Dowd BF, George SR (2006) Agonist-induced cell surface trafficking of an intracellularly sequestered D1 dopamine receptor homo-oligomer. Mol Pharmacol 70:78-89
24. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-8
25. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-51
26. Lee SP, O'Dowd BF, George SR (2003) Homo-and heterooligomerization of G protein-coupled receptors. Life Sci 74:173-80
27. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang YY, Simpson N, Ngo K, Van Heertum R, Laruelle M (2001) Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D-2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-57
28. Milligan G (2004) G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66:1-7
29. Mottola DM, BrewsterWK, Cook LL, Nichols DE, Mailman RB (1992) Dihydrexidine, a novel full efficacy D1-dopamine receptor agonist. J Pharmacol Exp Ther 262:383-93
30. Ryman-Rasmussen JP, Nichols DE, Mailman RB (2005) Differential activation of adenylate cyclase and receptor internalization by novel dopamine D-1 receptor agonists. Mol Pharmacol 68:1039-48
31. Schneider JS, Sun ZQ, Roeltgen DP (1994) Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed-response performance in chronic low-dose MPTP-treated monkeys. Brain Res 663:140-4
32. Seamans JK, Gorelova N, Durstewitz D, Yang CR (2001) Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci 21:3628-38
33. Seamans JK, Yang CR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74:1-57
34. Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu XY, Laruelle M, Abi-Dargham A (2007) [C-11] NNC 112 selectivity for dopamine D-1 and serotonin 5-HT2A receptors: a PET study in healthy human subjects. J Cereb Blood Flow Metab 27:1733-41
35. Trantham-Davidson H, Neely LC, Lavin A, Seamans JK (2004) Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J Neurosci 24:10652-9
36. Weiss JM, Morgan PH, Lutz MW, Kenakin TP (1996a) The cubic ternary complex receptor-occupancy model. 3. Resurrecting efficacy. J Theor Biol 181:381-97
37. Weiss JM, Morgan PH, Lutz MW, Kenakin TP (1996b) The cubic ternary complex receptor-occupancy model. 1. Model description. J Theor Biol 178:151-67
38. Weiss JM, Morgan PH, Lutz MW, Kenakin TP (1996c) The cubic ternary complex receptor-occupancy model. 2. Understanding apparent affinity. J Theor Biol 178:169-82